Canlyniadau Chwilio - Robb, M.

Isolation of hybridoma cell lines and characterization of monoclonal antibodies against cholera enterotoxin and its subunits. gan Robb, M, Nichols, J C, Whoriskey, S K, Murphy, J R

Cael y testun llawn
Cael y testun llawn
Cael y testun llawn

Gastrointestinal Colonization by Candida albicans Mutant Strains in Antibiotic-Treated Mice gan Wiesner, Stephen M., Jechorek, Robert P., Garni, Robb M., Bendel, Catherine M., Wells, Carol L.

Cael y testun llawn
Cael y testun llawn
Cael y testun llawn

Referral and access to care of HIV prevalent cases; experience from the early capture HIV cohort study in Kampala gan Mutengu LN, Kibuuka H, Millard M, Sekiziyivu A, Wakabi S, Nanyondo J, Kawooya G, Robb M, Michael N

Pattern of HIV risk behavior in a cohort of high risk women in East Africa gan Kibuuka HN, Rono K, Maganga L, Millard M, Sekiziyivu A, Maboko L, Shaffer D, Valenzuela A, Michael N, Robb M

Use of patient flow analysis to improve patient visit efficiency by decreasing wait time in a primary care-based disease management programs for anticoagulation and chronic pain: a... gan Shilliday Betsy, Malone Robb M, Potisek Nicholas M, Ives Timothy J, Chelminski Paul R, DeWalt Darren A, Pignone Michael P

Cael y testun llawn

Global distribution, trends, and drivers of flash drought occurrence gan Jordan I. Christian, Jeffrey B. Basara, Eric D. Hunt, Jason A. Otkin, Jason C. Furtado, Vimal Mishra, Xiangming Xiao, Robb M. Randall

Cael y testun llawn

Antibody-mediated inhibition of HIV-1 elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy Tanzanian adults gan Joachim A, Nilsson C, Aboud S, Lyamuya EF, Robb M, Marovich M, Ochsenbauer C, Wahren B, Sandström E, Biberfeld G, Ferrari G, Polonis VR

Early immune events during acute HIV infection gan Slike BM, Tassaneetrithep B, Nitayaphan S, Rono K, Sanga E, Sekiziyivu A, Stablein D, Eller L, Eller MA, Kim J, Michael N, Robb M, Marovich M

Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 a... gan Mascola, J R, Louder, M K, VanCott, T C, Sapan, C V, Lambert, J S, Muenz, L R, Bunow, B, Birx, D L, Robb, M L

Cael y testun llawn
Cael y testun llawn
Cael y testun llawn

Incident cases characterization and deep sequencing provide new insight into multiplicity of infection and HIV evolution in very early acute infection gan Kijak G, Sanders-Buell E, Rolland M, Li H, Bates A, Bose M, O'Sullivan A, Eller L, O'Connell R, Shaw G, Michael N, Kim J, Robb M, Tovanabutra S

Evidence for Env-V2 sieve effect in breakthrough SIV _MAC251 infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs gan Sina S, Tovanabutra S, Sanders-Buell E, Bates A, Bose M, Howell S, Ibitamuno G, Lazzaro M, O'Sullivan A, Lee J, Cervenka T, Kuroiwa J, Baldwin K, Barouch DH, Robb M, O'Connell R, Michael NL, Kim JH, Rolland M

P14-14 LB. A low dose of multigene, multiclade HIV DNA given intradermally induces strong and broad immune responses after boosting with heterologous HIV MVA gan Wahren B, Moss B, Earl P, Michael N, Marovich M, Robb M, Brave A, Hejdeman B, Stout R, Mwanyika L, Mbwana J, Janabi M, Lyamuya E, Aris EA, Moshiro C, Buma D, Francis J, Nilsson C, Aboud S, Bakari M, Biberfeld G, Pallangyo K, Mhalu F, Sandstrom E

Preferential targeting of conserved Gag regions after vaccination with a heterologous DNA prime Modified Vaccinia Ankara boost HIV vaccine regime gan Bauer A, Podola L, Haule A, Sudi L, Nilsson C, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, Joseph S, McCormack S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Kroidl A, Geldmacher C

Determinations of Levels of Human Immunodeficiency Virus Type 1 RNA in Plasma: Reassessment of Parameters Affecting Assay Outcome gan Lew, J., Reichelderfer, P., Fowler, M., Bremer, J., Carrol, R., Cassol, S., Chernoff, D., Coombs, R., Cronin, M., Dickover, R., Fiscus, S., Herman, S., Jackson, B., Kornegay, J., Kovacs, A., McIntosh, K., Meyer, W., Michael, N., Mofenson, L., Moye, J., Quinn, T., Robb, M., Vahey, M., Weiser, B., Yeghiazarian, T.

Cael y testun llawn
Cael y testun llawn
Cael y testun llawn

Breadth, phenotype and functionality of Gag-specific T cell responses induced by a heterologous DNA/MVA prime-boost HIV-1 vaccine regimen gan Podola L, Bauer A, Haule A, Sudi L, Nilsson C, Godoy-Ramirez K, Mann P, Missanga M, Kaluwa B, Maboko L, Lueer C, Mwakatima M, Aboud S, Bakari M, Currier J, Robb M, McCormack S, Joseph S, Lyamuya E, Hoelscher M, Wahren B, Sandström E, Biberfeld G, Geldmacher C, Kroidl A

Priming with a “simplified regimen” of HIV-1 DNA vaccine is as good as a “standard regimen” when boosted with heterologous HIV-1 MVA vaccine gan Munseri P, Kroidl A, Nilsson C, Moshiro C, Aboud S, Joachim A, Geldmacher C, Aris E, Buma D, Lyamuya E, Gotch F, Godoy-Ramirez K, Pallangyo K, Maboko L, Marovich M, Robb M, Hoelscher M, Janabi M, Mann P, Joseph S, Mfinanga S, Stoehr W, Mhalu F, Wahren B, Biberfeld G, McCormack S, Sandstrom E, Bakari M